Ekso Bionics Holdings Stock Performance
| EKSO Stock | USD 0.48 0.02 4.00% |
The firm shows a Beta (market volatility) of -1.17, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Ekso Bionics are expected to decrease by larger amounts. On the other hand, during market turmoil, Ekso Bionics is expected to outperform it. At this point, Ekso Bionics Holdings has a negative expected return of -0.14%. Please make sure to confirm Ekso Bionics' value at risk, as well as the relationship between the skewness and day median price , to decide if Ekso Bionics Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ekso Bionics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
Last Split Factor 1:15 | Dividend Date 2020-03-25 | Last Split Date 2020-03-25 |
1 | Disposition of 15599 shares by Steven Sherman of Ekso Bionics subject to Rule 16b-3 | 01/15/2025 |
2 | Ekso Bionics Holdings Enterprise Value 12.88 Mil - GuruFocus.com | 01/17/2025 |
3 | Neurorehabilitation Devices Market Size to Reach US 7.09 Billion by 2031, Driven by Technological Advancements and Rising Neurological Disorders | 01/28/2025 |
4 | Rehabilitation Robots Market Size Expected to Reach USD 1776.24 Mn by 2034 | 02/21/2025 |
5 | Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 Conference Call to Follow | 02/24/2025 |
6 | Ekso Bionics Q4 Earnings Snapshot | 03/03/2025 |
7 | Q4 2024 Ekso Bionics Holdings Inc Earnings Call Transcript | 03/04/2025 |
8 | Ekso Bionics Holdings, Inc. Consensus Forecasts Have Become A Little Darker Since Its Latest Report | 03/06/2025 |
9 | Acquisition by Scott Davis of 5590 shares of Ekso Bionics subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 8.6 M | |
| Free Cash Flow | -9.8 M |
Ekso |
Ekso Bionics Relative Risk vs. Return Landscape
If you would invest 61.00 in Ekso Bionics Holdings on December 24, 2024 and sell it today you would lose (11.00) from holding Ekso Bionics Holdings or give up 18.03% of portfolio value over 90 days. Ekso Bionics Holdings is currently does not generate positive expected returns and assumes 6.165% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Ekso, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ekso Bionics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ekso Bionics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ekso Bionics Holdings, and traders can use it to determine the average amount a Ekso Bionics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0228
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EKSO |
Estimated Market Risk
| 6.17 actual daily | 55 55% of assets are less volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ekso Bionics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ekso Bionics by adding Ekso Bionics to a well-diversified portfolio.
Ekso Bionics Fundamentals Growth
Ekso Stock prices reflect investors' perceptions of the future prospects and financial health of Ekso Bionics, and Ekso Bionics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ekso Stock performance.
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.44) % | ||||
| Current Valuation | 11.16 M | ||||
| Shares Outstanding | 24.82 M | ||||
| Price To Earning | (0.67) X | ||||
| Price To Book | 0.92 X | ||||
| Price To Sales | 0.69 X | ||||
| Revenue | 17.93 M | ||||
| Gross Profit | 9.51 M | ||||
| EBITDA | (9.45 M) | ||||
| Net Income | (11.33 M) | ||||
| Cash And Equivalents | 31.91 M | ||||
| Cash Per Share | 2.45 X | ||||
| Total Debt | 5.98 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 8.16 X | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (9.85 M) | ||||
| Earnings Per Share | (0.56) X | ||||
| Market Capitalization | 12.41 M | ||||
| Total Asset | 26.65 M | ||||
| Retained Earnings | (250.47 M) | ||||
| Working Capital | 11.31 M | ||||
| Current Asset | 17.57 M | ||||
| Current Liabilities | 5.51 M | ||||
About Ekso Bionics Performance
By examining Ekso Bionics' fundamental ratios, stakeholders can obtain critical insights into Ekso Bionics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Ekso Bionics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 198.29 | 118.13 | |
| Return On Tangible Assets | (0.52) | (0.55) | |
| Return On Capital Employed | (0.55) | (0.57) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.89) | (0.94) |
Things to note about Ekso Bionics Holdings performance evaluation
Checking the ongoing alerts about Ekso Bionics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ekso Bionics Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ekso Bionics generated a negative expected return over the last 90 days | |
| Ekso Bionics has high historical volatility and very poor performance | |
| Ekso Bionics has some characteristics of a very speculative penny stock | |
| Ekso Bionics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 17.93 M. Net Loss for the year was (11.33 M) with profit before overhead, payroll, taxes, and interest of 9.51 M. | |
| Ekso Bionics Holdings currently holds about 31.91 M in cash with (9.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ekso Bionics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Scott Davis of 5590 shares of Ekso Bionics subject to Rule 16b-3 |
- Analyzing Ekso Bionics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ekso Bionics' stock is overvalued or undervalued compared to its peers.
- Examining Ekso Bionics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ekso Bionics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ekso Bionics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ekso Bionics' stock. These opinions can provide insight into Ekso Bionics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ekso Bionics. If investors know Ekso will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ekso Bionics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Revenue Per Share | Quarterly Revenue Growth 0.05 | Return On Assets | Return On Equity |
The market value of Ekso Bionics Holdings is measured differently than its book value, which is the value of Ekso that is recorded on the company's balance sheet. Investors also form their own opinion of Ekso Bionics' value that differs from its market value or its book value, called intrinsic value, which is Ekso Bionics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ekso Bionics' market value can be influenced by many factors that don't directly affect Ekso Bionics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ekso Bionics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ekso Bionics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ekso Bionics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.